Patacchini Elisa, Madia Valentina Noemi, Albano Aurora, Ruggieri Giuseppe, Messore Antonella, Ialongo Davide, Saccoliti Francesco, Scipione Luigi, Cosconati Sandro, Koneru Pratibha C, Haney Reed, Kvaratskhelia Mamuka, Di Santo Roberto, Costi Roberta
Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185 Rome, Italy.
DiSTABiF, University of Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100 Caserta, Italy.
ACS Med Chem Lett. 2024 Aug 5;15(9):1533-1540. doi: 10.1021/acsmedchemlett.4c00268. eCollection 2024 Sep 12.
The HIV-1 integrase (IN) plays a critical role in the viral lifecycle by integrating the viral DNA into the host chromosome. The catalytic function of IN has been exploited as a target, with five drugs acting as active site binders (IN strand transfer inhibitors, INSTIs). However, IN mutations conferring low-level resistance to INSTIs have been reported. Therefore, new IN inhibitors with different mechanisms of action are needed. The allosteric inhibition of IN, exerted by allosteric IN inhibitors (ALLINIs), is gaining interest. ALLINIs inhibit IN by inducing aberrant IN multimerization with different mechanisms. Furthermore, recent discoveries unveiled that IN has an under-studied yet equally vital second function. This involves IN binding to the RNA genome in virions, necessary for proper virion maturation. In this work, we describe a series of quinolinonyl derivatives as inhibitors of both the IN catalytic functions and IN-RNA interactions, which impair both early and late steps of viral replication.
HIV-1整合酶(IN)通过将病毒DNA整合到宿主染色体中,在病毒生命周期中发挥关键作用。IN的催化功能已被用作靶点,有五种药物作为活性位点结合剂(IN链转移抑制剂,INSTIs)。然而,已有报道称IN发生了对INSTIs低水平耐药的突变。因此,需要具有不同作用机制的新型IN抑制剂。变构IN抑制剂(ALLINIs)对IN的变构抑制作用正受到关注。ALLINIs通过不同机制诱导异常的IN多聚化来抑制IN。此外,最近的发现揭示IN还有一个研究较少但同样重要的第二功能。这涉及IN与病毒粒子中的RNA基因组结合,这对病毒粒子的正常成熟是必要的。在这项工作中,我们描述了一系列喹啉onyl衍生物作为IN催化功能和IN-RNA相互作用的抑制剂,它们会损害病毒复制的早期和晚期步骤。